How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bacterial-infection-due-to-serratia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bacterial infection due to Serratia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bacterial infection due to Serratia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bacterial infection due to Serratia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
AZLOCILLIN	AZLOCILLIN	Bayer Pharmaceuticals Corp	azlocillin		1982-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Tobi	tobramycin	Novartis		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in Bacterial infection due to Serratia
Bristol-Myers Squibb · 2 drugs in Bacterial infection due to Serratia
Merck & Co. · 2 drugs in Bacterial infection due to Serratia
Centre Hospitalier Universitaire Vaudois · 1 drug in Bacterial infection due to Serratia
Generic (originally Roche) · 1 drug in Bacterial infection due to Serratia
Bayer Pharmaceuticals Corp · 1 drug in Bacterial infection due to Serratia
Novartis · 1 drug in Bacterial infection due to Serratia
Pfizer · 1 drug in Bacterial infection due to Serratia
Sterimax · 1 drug in Bacterial infection due to Serratia
University Hospital, Lille · 1 drug in Bacterial infection due to Serratia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bacterial infection due to Serratia:

Cite this brief

Drug Landscape (2026). Bacterial infection due to Serratia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bacterial-infection-due-to-serratia. Accessed 2026-06-10.

Bacterial infection due to Serratia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing